Enhanced Growth Hormone Antagonist Combinations for Targeted Cancer Therapy

This inventive concept discloses novel combinations of modified human growth hormone receptor antagonists with chemotherapeutic drugs, targeting specific cancer cells to improve treatment efficacy and reduce toxicity.

The original patent disclosed a composition for treating cancer using a modified human growth hormone receptor antagonist. However, the original patent had limitations in terms of targeting specific cancer cells and reducing toxicity. The new inventive concept addresses these limitations by introducing targeted combination therapies that selectively bind to cancer cells expressing predetermined levels of growth hormone receptor and prolactin receptor.

The new inventive concept comprises a system for treating cancer, wherein a modified human growth hormone receptor antagonist is combined with a chemotherapeutic drug. The antagonist is selectively targeted to cancer cells expressing predetermined levels of growth hormone receptor and prolactin receptor. The combination therapy enhances the efficacy of the chemotherapeutic drug while reducing toxicity. The antagonist can be conjugated to a polyethylene glycol molecule with a maleimide group or a branched structure, which improves its pharmacokinetics and targeting capabilities.

The new claims introduce novel combinations of modified human growth hormone receptor antagonists with chemotherapeutic drugs, which are selectively targeted to specific cancer cells. This targeting approach is new and non-obvious compared to the original patent, which did not disclose such combinations or targeting mechanisms.

Alternative embodiments of the inventive concept include using different chemotherapeutic drugs, modifying the polyethylene glycol molecule with different functional groups, or using different types of growth hormone receptor antagonists. These variations can be used to target different types of cancer or to improve the pharmacokinetics of the combination therapy.

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of targeted therapies and combination treatments. The market for cancer treatments is growing rapidly, and this inventive concept can provide a competitive advantage in terms of efficacy and safety.